Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned a consensus rating of “Buy” from the thirteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $108.75.

Several research analysts recently weighed in on MNPR shares. BTIG Research boosted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating and issued a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd.

Monopar Therapeutics Stock Up 5.3%

NASDAQ MNPR opened at $104.50 on Friday. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $112.57. The company has a 50 day moving average price of $69.94 and a 200 day moving average price of $63.57. The firm has a market cap of $700.15 million, a PE ratio of -55.00 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.41. On average, equities research analysts anticipate that Monopar Therapeutics will post -2.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Ally Bridge Group NY LLC lifted its stake in shares of Monopar Therapeutics by 86.6% during the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after buying an additional 29,918 shares during the period. Virtu Financial LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at $654,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at $86,000. Mountain Pacific Investment Advisers LLC purchased a new position in Monopar Therapeutics in the 4th quarter worth $398,000. Finally, TD Asset Management Inc purchased a new position in Monopar Therapeutics in the 4th quarter worth $201,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.